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Abstract: Preoperative chemoradiotherapy (CRT) and lateral pelvic lymph node (LPLN) 
dissection (LPLD) based on pretreatment imaging are performed to improve oncological 
outcomes at our institution. However, the advantage of LPLD following preoperative CRT in 
advanced rectal cancer remains unclear. The objective of the present study was to assess the valid-
ity of this approach. Thirty-two patients with advanced rectal cancer were included in the study. 
All patients were treated with preoperative CRT and curative operation. Of these, 16 patients 
who were treated between August 2005 and June 2008 underwent LPLD on both sides (LPLD 
group). Sixteen patients who were treated between July 2008 and January 2013 underwent 
LPLD only on the side with suspected LPLN metastasis determined by pretreatment imaging; 
in cases without LPLN metastasis, only total mesorectal excision was performed (limited-LPLD 
group). The overall survival and relapse-free survival between the LPLD and the limited-LPLD 
groups were compared. Preoperative CRT was able to lower clinical lymph node status in 50% 
of the cases. In addition, pathological lymph node status did not exceed the pretreatment clinical 
lymph node status stage in the LPLD group. There were no differences in the overall survival 
and relapse-free survival between the two groups (P=0.729 and P=0.874, respectively). We 
conclude that multi-imaging studies have a very low risk of overlooking pathologically positive 
LPLN metastases. Therefore, limited LPLD is a feasible strategy for patients with advanced 
rectal cancer and suspicious LPLN metastases based on pretreatment imaging.
Keywords: neoadjuvant treatment, rectal cancer, chemoradiotherapy, lateral pelvic lymph node, 
MRI, CT
Introduction
Total mesorectal excision (TME) with preoperative chemoradiotherapy (CRT) is a 
widely accepted standard treatment for patients with advanced rectal cancer. However, 
the dissection of lateral pelvic lymph nodes (LPLNs) remains controversial. In Japan, 
the Japanese Society for Cancer of the Colon and Rectum (JSCCR) 2010 guidelines 
for the treatment of colorectal cancer recommends dissecting the LPLN, because of an 
increased risk for LPLN metastasis when advanced-stage lower rectal cancer extends 
below the peritoneal reflection.1 In Western countries, LPLN dissection (LPLD) is gener-
ally not performed because LPLD shows no benefit over adjuvant CRT,2 and there are 
no differences in local recurrence rates between preoperative radiation and LPLD.3,4
To improve the oncologic outcomes in patients with advanced rectal cancer, we 
have been performing preoperative CRT and bilateral LPLD at our institution, with 
good local control. The local recurrence rates have been acceptable, and there were 
no LPLN metastases that were initially diagnosed as negative during pretreatment 
imaging; however, patients had LPLD-related complications. Thus, we hypothesized 
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that limiting LPLD would minimize the side effects of LPLD 
with minimal negative surgical outcomes. The objective of 
the current study was to assess the clinical validity of limiting 
LPLD in patients with advanced rectal cancer.
Patients and methods
study population
In total, 32 patients with biopsy-proven, locally advanced 
(clinical primary tumor status of cT3–4 or positive clinical 
lymph node status) rectal cancer with the lower tumor border 
located above and bellow the peritoneal reflection were 
treated at Kobe University Hospital between August 2005 and 
June 2013. All study participants provided written informed 
consent, and the study design was approved by the ethics 
review board at Kobe University Hospital and conforms to 
the provisions of the Declaration of Helsinki.
staging
The TNM stage was determined according to the seventh edi-
tion of the AJCC Cancer Staging Manual.5 According to the 
JSCCR classification, the lateral pelvic area is classified into 
four regions: internal iliac, obturator, external iliac, and common 
iliac.6 Although all LPLNs are not defined clearly as regional 
lymph nodes in the AJCC manual, we classified all LPLNs as 
such, based on a previous study by Akiyoshi et al.7
Clinical stage assessment was based on computed tomog-
raphy (CT), magnetic resonance imaging (MRI), and positron 
emission tomography (PET) studies. We defined lymph node 
metastasis as positive in the presence of one or more of the 
following: a lymph node larger than 8 mm by CT; a positive 
diffusion-weighted image by MRI; or a high-intensity spot 
by PET. However, the definitive determination for LPLD 
was made at the surgical team meetings. The imaging studies 
were conducted before CRT and 4–6 weeks following CRT 
to evaluate the clinical stage.
Treatment strategy
Patients received chemotherapy that consisted of tegafur–
uracil (UFT) 200 mg/m2/day and leucovorin (LV) 75 mg/
body/day for 28 days and radiotherapy at a total dose of 
45 Gy. The lateral pelvic area was included in the radiation 
target volume. Surgery was performed 6–8 weeks after the 
completion of the preoperative CRT. LPLD was performed 
according to the JSCCR 2010 guidelines.1 All patients treated 
between August 2005 and June 2008 underwent bilateral 
LPLD (LPLD group, 16 patients). After July 2008, LPLD 
was performed on the side that was suspected positive for 
LPLN metastasis by pretreatment imaging, irrespective of the 
posttreatment imaging results; TME alone was performed on 
patients for whom preoperative imaging showed an absence 
of LPLN metastasis (limited-LPLD group, 16 patients).
statistical analysis
Descriptive statistics were performed using the JMP statisti-
cal software package (JMP® 10; SAS Institute Inc., Cary, NC, 
USA). The LPLD and limited-LPLD groups were compared 
using the χ2 test or the Fisher’s exact test. Overall survival 
(OS) was calculated from the date of confirmed diagnosis 
at our hospital to the occurrence of the event or to the last 
known date of follow-up. Survival analysis was performed 
using the Kaplan–Meier method with the log-rank test. In 
all analyses, a P-value ,0.05 was accepted as statistically 
significant.
Results
In the limited-LPLD group, nine patients were diagnosed as 
LPLN-positive based on pretreatment imaging. However, ten 
patients received limited LPLD: one patient received LPLD 
based on intraoperative findings, despite negative preopera-
tive imaging results. There were no differences between the 
LPLD and limited-LPLD groups in patient characteristics, 
except for age (Table 1). Only one patient in the LPLD group 
had pathological LPLN metastasis, whereas three patients in 
the limited-LPLD group had LPLN metastases. The median 
follow-up periods for the LPLD and limited-LPLD groups 
were 7.8 (range: 0.9–9.5) years and 3.6 (range: 1.1–6.6) years, 
respectively.
The changes in lymph node status in relation to preop-
erative CRT are listed in Table 2. In all cases, pathological 
lymph node status did not exceed the pretreatment clinical 
lymph node status, suggesting that all LPLN metastases were 
successfully diagnosed preoperatively. None of the cases 
were false positive for LPLN metastases. In 50% of the cases, 
the lymph node status improved after preoperative CRT. 
In the LPLD group, the percentage of pathological LPLN 
status metastasis was 6.3% (one in 16 patients), and no false-
negatives were observed. The numbers of local and distant 
recurrences observed in each group are listed in Table 3. 
No LPLN recurrence was observed in either the LPLD or 
the limited-LPLD group. Local and distant recurrence rates 
did not differ between the two groups.
The median operation time and the amount of lost 
blood were 405 minutes (range: 280–603) and 754.5 mL 
(range: 343–2,386), respectively, in the LPLD group, 
and 596 minutes (range: 382–858) and 715 mL (range: 
100–5,345), respectively, in the limited-LPLD group. Surgical 
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site infection was observed in 12 patients (75.0%) in the LPLD 
group and seven patients (43.8%) in the limited-LPLD group. 
Urinal dysfunction was observed in five patients (33.3%) in 
the LPLD group. In the limited-LPLD group, ten patients 
received LPLD and four patients (40.0%) had urinal dysfunc-
tion; two of these patients underwent bilateral LPLD.
Figure 1A represents the OS in the LPLD and limited-
LPLD groups. The relapse-free survival (RFS) for the two 
groups is shown in Figure 1B. No significant differences 
were observed in the OS and the RFS between the two groups 
(P=0.729 and P=0.874, respectively).
Discussion
Based on the results of the German Rectal Cancer Study Group 
trial, preoperative CRT has become a standard treatment for 
rectal cancer in Western countries.8 There are several studies 
which assessed 5-fluorouracil (FU)/LV as pretreatment 
chemotherapy; however, there are no randomized trials to 
date.9,10 Ishihara et al reported the efficacy of UFT/LV with 
radiotherapy as a preoperative treatment for rectal cancer with 
no increases in postoperative complications.11 Histologically 
proven downstaging was observed in 42%–60% of patients, 
and 3-year OS was 86%–90% in patients treated with 
UFT/LV with radiotherapy.12,13
Table 1 Patient and tumor characteristics
Variables LPLD group Limited-LPLD 
group
P-value
number of patients n=16 n=16
Period 2005–2008 2008–2013
Follow-up period,  
years median (range)
7.8 (0.92–9.45) 3.6 (1.07–6.64) 0.002*
age, years mean (sD) 61.3 (8.9) 68.4 (5.9) 0.012
sex 0.685
Female 5 3
Male 11 13
Tumor site 1.000
high rectum 2 2
low rectum 14 14
clinical T stage 0.710
cT3 10 11
cT4 6 5
clinical n stage 0.685
cn- 5 3
cn+ 11 13
clinical lPln metastasis 0.480
Present 7 9
absent 9 7
histological type 0.333
Well/moderately 
differentiated
12 15
Mucinous/poorly 
differentiated
3 1
Operative procedure 0.394
anterior resection 5 2
abdominal perineal  
resection
11 14
ypT 0.059
ypT0–2 8 3
ypT3–4 8 13
ypn 0.464
ypn- 11 5
ypn+ 9 7
yplPln metastasisa 0.264
Present patients/lPlD 
patients
1/16 3/10
absent patients/lPlD  
patients
15/16 7/10
Pathological grade 0.514
1 6 8
2 7 7
3 3 1
circumferential  
resection margin
0.226
Positive 0 3
negative 16 13
lymphovascular invasion 11 7 0.152
adjuvant chemotherapy 9 10 0.719
Notes: asix patients did not have lPlD since there were no positive lPln 
metastases according to the preoperative imaging. One patient received lPlD based 
on intraoperative findings, despite negative preoperative imaging results. *indicates 
statistically significant.
Abbreviations: cn, clinical lymph node status; lPlD, lateral pelvic lymph node 
dissection; lPln, lateral pelvic lymph node; sD, standard deviation; ypn, pathological 
lymph node status; yplPln, pathological lPln status; clPln, clinical lPln status.
Table 2 lymph node statuses in patients who underwent bilateral 
lPlD
Pathological lymph node metastasis
ypN- ypN+
ypLPLN- ypLPLN+
Pretreatment clinical lymph node metastasis
cn- 5 0 0
clPln- 2 2 0
cn+
clPln+ 4 2 1
Abbreviations: cn, clinical lymph node status; lPlD, lateral pelvic lymph node 
dissection; ypn, pathological lymph node status; lPln, lateral pelvic lymph node; 
yplPln, pathological lPln status; clPln, clinical lPln status.
Table 3 number of recurrences
Cases (%) P-value
local recurrence
lPlD group 2 (12.5) 1.000
limited-lPlD group 1 (6.3)
Distant recurrence
lPlD group 3 (18.8) 1.000
limited-lPlD group 4 (25.0)
lPln recurrence
lPlD group 0 (0) 1.000
limited-lPlD group 0 (0)
Abbreviations: lPlD, lateral pelvic lymph node dissection; lPln, lateral pelvic 
lymph node.
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Several previous reports argue that pretreatment imaging 
may not be able to detect all pathologically positive 
LPLNs14,15 and that the number of false-negative LPLNs 
might be higher than that predicted.16 Our results show 
the accuracy of pretreatment diagnosis, with the absence 
of false-negative LPLNs in the LPLD group. This finding 
could be because of the combination of CT, MRI, and PET 
for assessment, resulting in an accurate diagnosis, and CRT 
for the improved management of LPLN metastases.
In Western countries, preoperative CRT is a standard 
treatment that has led to low local recurrence rates.8 However, 
CRT cannot manage all clinically positive LPLN metastases, 
as was the case in one of our patients with a pathologically 
positive LPLN, in agreement with a previous report.17 We 
believe that CRT alone cannot fully manage LPLN metas-
tases; thus, LPLD provides an opportunity to control local 
recurrence following CRT.
LPLD is associated with a number of complications, 
including prolonged operation time, increased blood 
loss, and increased frequency of urinary and male sexual 
dysfunction, compared with those observed in patients who 
did not undergo LPLD.3 Thus, patients with suspicious 
LPLN should receive limited LPLD. We performed both 
CRT and LPLD based on the assessment by pretreatment 
imaging. The amount of blood loss was comparable 
between the two groups; however, the operation time 
was significantly longer for the limited-LPLD group than 
that for the LPLD group. As we have already mentioned, 
neither the LPLD group nor the limited-LPLD group 
experienced an LPLN recurrence. The limited-LPLD 
group had an OS and RFS that was equivalent to the LPLD 
group. Further, there were no false-negative LPLN cases 
in the LPLD group. These results suggest that determining 
suspicious LPLN metastases by pretreatment imaging is 
feasible and that limiting LPLD is associated with favor-
able surgical outcomes.
This study has certain potential limitations. First, the 
number of patients was relatively small, and the follow-up 
period for some patients was not long enough to most 
adequately evaluate the rate of recurrence. Second, we per-
formed LPLD in all cases in which lymph node metastasis 
was suspected by imaging. This approach may have led to an 
increase in the enrollment of candidates for LPLD, because 
several studies have shown that a post-CRT LPLN .5 mm in 
diameter is significantly associated with metastasis.18,19 In the 
present study, each of the four patients who had pathologi-
cally positive LPLN metastases before treatment still had 
LPLNs of $8 mm after CRT. Thus, the imaging criteria of 
LPLN metastasis in patients treated with preoperative CRT 
are reliable and necessary to determine those who need to 
undergo LPLD.
Conclusion
Treatment with preoperative CRT and LPLD is advantageous 
in managing local recurrence. Advances in multi-imaging 
studies help to avoid overlooking pathologically positive 
LPLN metastases. Therefore, limiting LPLD is a feasible 
strategy for patients with advanced rectal cancer and suspi-
cious LPLN metastasis following CRT.
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Figure 1 There was no difference in overall survival (A) or relapse-free survival (B) between the limited-lPlD and lPlD groups.
Notes: The solid line represents the lPlD group and the dotted line represents the limited-lPlD group. lPlD group, patients who underwent bilateral lPlD. limited-lPlD 
group, patients who underwent lPlD only on the side with suspected lateral pelvic lymph node (lPln) metastasis; TMe was performed on patients in whom lPln was not 
suspected by pretreatment imaging.
Abbreviation: lPlD, lateral pelvic lymph node dissection.
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